The two companies that have grown the most in the Mab in 2016 are focused on the software sector. Facephi is an example of a company that in 2016 is seeing a recovery after difficult years, while Alitia is an example of a company that Mab has helped to grow to become one of the leaders in its sector.
M&A advisors with expertise in the technology sector
MAB
Latest Sectoral Reports |
Last Entries
The MAB, a means to close acquisitions?
MAB companies have started the new year with growth. Some, such as Eurona Wireless, have carried out capital increases in order to finance acquisitions, while others, such as Agile Content, have announced the purchase of companies. In addition, Inkemia has increased its shareholdings in its group companies through capital increases.
New additions to the MAB: Voztelecom and Atrys Health
In July, two new companies joined the MAB in the expansion capital category. One in the biotechnology sector, Atrys Health, and another in the telecommunications sector, Voztelecom. In addition, listed companies such as Mosmovil and Ab Biotics are making deals.
Atrys to list on Mab tomorrow (Friday) after capital increase
Atrys will make its debut tomorrow on the MAB, after receiving the approval of the MAB incorporations committee. The company, which is the 35th company to be listed in the growth company category, is engaged in the provision of diagnostic services and medical treatments and the development of new therapeutic modalities and diagnostic tools.
MAB-listed Catalana Agile buys US, Brazil and Spain-based OTTN for $$7.9M.
Agile, which specialises in audiovisual content management and Big Data for audience segmentation, has acquired Over-The-Top (OTTN), which develops technology for pay-TV platforms, enabling a new TV experience through video-on-demand consumption.
MAB as a form of inorganic growth: Clerph and Inkemia
One of the advantages of a MAB listing is the generation of liquidity that allows the company to grow inorganically. As proof of this, in the last year we have seen several companies from very different sectors listed on the MAB that have made acquisitions, such as Clerph, Inkemia, or Bionaturis.
Clerhp structures exits the mab up 10.24%
On 8 March, Clerp, an engineering company that wants to grow in the Latin American market, was listed on the MAB as a growth company.
TECNOQUARK goes public on the MAB to finance growth
At the end of 2015, 9 companies in the expansion phase have debuted this year on the MAB, with a revenue of close to €100M. This represents an increase in the number of MAB companies of 30% compared to the end of 2014 and shows signs of optimism for 2016, in which companies such as BestPrice have already shown their interest in listing on the MAB.
Oryzon genomics floats on the MAB
Oryzon Genomics is now listed on the MAB, reinforcing the biotech market, which is the largest listed on the MAB. Of the 33 companies listed on the MAB, 8 are active in the biotechnology sector.
The MAB, alternative financing that is making a comeback
After a year in which the Gowex scandal meant that only Socimis were listed on the MAB, the strict regulation of the market has won back the support of investors and several companies are choosing this market as a way to grow. Today Agile Contents went public and last week Thinksmart.
Spanish biotechs go public
It is not uncommon for the biotech sector to be punished at times in the stock market because of traditional bubbles and high valuations. However, the S&P Biotechnology select Industry index shows that the situation has improved and has risen by 11% since January. Moreover, of the just over 200 biotechs listed on Wall Street, none of them have a sell recommendation. In fact, experts are betting to buy or overweight around 190 of them.
The MAB raised €40MM in 2012
According to Capital & corporate in its annual report, the MAB (alternative stock market for SMEs) has maintained the levels of activity of 2011 with €8.5 million from 5 new incorporations and just over €30 million in 6 capital increases.